Biogen scraps development of therapy for rare brain disease
(Reuters) – Biogen Inc said on Friday it would discontinue the development of its experimental therapy for a rare brain disease after the treatment failed a mid-stage trial, the latest…
Multiple sclerosis drug helps Biogen beat Wall St. profit expectations
(Reuters) – Biogen Inc reported better-than-expected second quarter profit and raised its 2019 earnings forecast on Tuesday, driven by higher sales of its top-selling multiple sclerosis drug Tecfidera and lower…
Biogen scraps two Alzheimer drug trials, wipes $18 billion from market value
CHICAGO/TOKYO (Reuters) – Biogen Inc and partner Eisai Co Ltd are ending two late-stage trials of their experimental Alzheimer’s disease drug aducanumab, a major setback in the quest to find…
Novartis gene therapy would be cost effective up to $900,000: U.S. group
(Reuters) – An experimental gene therapy for spinal muscular atrophy (SMA) developed by Swiss drugmaker Novartis AG would be worth a price of $310,000 to $900,000, according to an independent…
Biogen’s pricey muscle drug Spinraza too costly for Britain
LONDON (Reuters) – Biogen’s muscle disease treatment Spinraza has been deemed too expensive for use on Britain’s state-run health service, even after a price discount offered by the U.S. drugmaker.…